Study identification

PURI

https://redirect.ema.europa.eu/resource/36269

EU PAS number

EUPAS20687

Study ID

36269

Official title and acronym

Longitudinal study on the epidemiology and management of auto-immune thrombocytopenia (AITP) in Algeria

DARWIN EU® study

No

Study countries

Algeria

Study description

Epidemiological, national, prospective, longitudinal study about the management of patients with auto-immune thrombocytopenia followed up by hematologists in the public sector in Algeria.

Study status

Finalised
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution
Multiple centres: 16 centres are involved in the study

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen
Study protocol
Initial protocol
English (557.28 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable